Evidence map›Paper›PMID 31467081›Full record

ArticleThe Journal of biological chemistry2019

Phosphoinositide 3-kinase δ inactivation prevents vitreous-induced activation of AKT/MDM2/p53 and migration of retinal pigment epithelial cells.

Haote Han, Na Chen, Xionggao Huang, Bing Liu, Jingkui Tian, Hetian Lei

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Haote HanSchepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts 02114.
Na ChenSchepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts 02114.
Xionggao HuangSchepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts 02114.
Bing LiuSchepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts 02114.
Jingkui TianCollege of Biomedical Engineering and Instrument Science, Zhejiang University, Hangzhou 310027, China.
Hetian LeiSchepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts 02114 Hetian_lei@meei.harvard.edu.ORCID 0000-0003-4091-1936
Massachusetts Eye and Ear Infirmary · USZhejiang University · CN

Funding

PDGF and PVRR01EY012509 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI LEI, HETIAN · 2000 to 2017
$8.5M
NEI NIH HHS R01 EY012509
6 · The paper itself

Abstract

Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that play a critical role in transmitting signals from cell-surface molecules to intracellular protein effectors. Key PI3Ks include PI3Kα, PI3Kβ, and PI3Kδ, which are regulated by receptors. The signaling pathway comprising the PI3Ks, along with a Ser/Thr kinase (AKT), a proto-oncogene product (mouse double minute (MDM)2), and a tumor suppressor protein (p53), plays an essential role in experimental proliferative vitreoretinopathy (PVR), which is a fibrotic blinding eye disorder. However, which PI3K isoforms are involved in PVR is unknown. A major characteristic of PVR is the formation of epi (or sub)-retinal membranes that consist of extracellular matrix and cells, including retinal pigment epithelium (RPE) cells, glial cells, and macrophages. RPE cells are considered key players in PVR pathogenesis. Using immunoblotting and immunofluorescence analyses, we herein provide the evidence that PI3Kδ is highly expressed in human RPEs when it is primarily expressed in leukocytes. We also found that PI3Kδ inactivation through two approaches, CRISPR/Cas9-mediated depletion and a PI3Kδ-specific inhibitor (idelalisib), not only blocks vitreous-induced activation of AKT and MDM2 but also abrogates a vitreous-stimulated decrease in p53. Furthermore, we demonstrate that PI3Kδ inactivation prevents vitreous-induced proliferation, migration, and contraction of human RPEs. These results suggest that PI3Kδ may represent a potential therapeutic target for RPE-related eye diseases, including PVR.

Indexed as

Cell MovementCell ProliferationClass I Phosphatidylinositol 3-KinasesEpithelial CellsHumansProto-Oncogene MasProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-mdm2Retinal Pigment EpitheliumSignal TransductionTumor Suppressor Protein p53Vitreous BodyClass I Phosphatidylinositol 3-KinasesMAS1 protein, humanPIK3CD protein, humanProto-Oncogene MasProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53Akt PKBmigrationmouse double minute 2 homolog (MDM2)p53phosphatidylinositide 3-kinase (PI 3-kinase)

Identifiers

PMID31467081
PMCPMC6802499
OpenAlexW2970747811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.